Article
Pharmacology & Pharmacy
Kuang-Ming Liao, Ka-Lok Lio, Yu-Ju Chou, Chen-Chun Kuo, Chung-Yu Chen
Summary: The study aimed to evaluate the relationship between OAB medication adherence and different types of medication with UTI risk. The study found that during the follow-up period, neither adherence nor different types of medication had an impact on UTI risk, regardless of UTI history or sex.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Urology & Nephrology
Hee Seo Son, Cheol Young Oh, Myung-Soo Choo, Hyeong Gon Kim, Joon Chul Kim, Kyu-Sung Lee, Dong Gil Shin, Sung Yong Cho, Seong Jin Jeong, Ju Tae Seo, Hana Yoon, Hong Sang Moon, Jang Hwan Kim
Summary: DA-8010, a novel muscarinic M3 receptor antagonist, has shown significant efficacy in treating overactive bladder with minimal side effects.
INTERNATIONAL NEUROUROLOGY JOURNAL
(2022)
Article
Plant Sciences
Lih-Lian Chen, Yuh-Chiang Shen, Chih-Chun Ke, Zuha Imtiyaz, Hui- Chen, Chin-Hsien Chang, Mei-Hsien Lee
Summary: The study indicates that treatment with cinnamon patch may be an effective and safe complementary therapy for overactive bladder (OAB), leading to significant improvements in OAB symptoms.
Review
Urology & Nephrology
Evgenyi I. Kreydin, Cristiano M. Gomes, Francisco Cruz
Summary: Overactive bladder is a common symptom complex that significantly impacts quality of life. Various medications are available for the treatment of OAB, and it is important to personalize treatment based on the patient's characteristics and expectations.
INTERNATIONAL BRAZ J UROL
(2021)
Article
Biochemistry & Molecular Biology
Paulina Iwaniak, Piotr Dobrowolski, Jan Wrobel, Tomasz Kluz, Artur Wdowiak, Iwona Bojar, Klaudia Stangel-Wojcikiewicz, Ewa Poleszak, Artur Jakimiuk, Marcin Misiek, Lukasz Zapala, Andrzej Wrobel
Summary: The study suggests that imperatorin has the potential to alleviate the symptoms of overactive bladder syndrome and improve bladder function and biochemical changes. Its mechanisms of action are diverse and complex, making it a promising candidate for the treatment of OAB.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Shunye Su, Liqin Hang, Jinlei Lin, Ludong Liu, Zhipeng Chen, Yuan Gao
Summary: Vibegron and antimuscarinic show similar therapeutic effects in treating OAB, but Vibegron demonstrates better tolerance and does not increase the risk of adverse events.
Article
Oncology
Wang Li, Yanduo Lin, Hong Xie, Qiang Fu, Rong Chen, Xiaoyong Hu, Jianwen Huang, Jihong Wang, Ranxing Yang
Summary: This study evaluated the effects of mirabegron in the treatment of overactive bladder syndrome (OAB) after radical prostatectomy (RP). The results showed that daily administration of 50 mg mirabegron significantly improved the symptoms of OAB after surgery with fewer side effects.
FRONTIERS IN ONCOLOGY
(2023)
Review
Obstetrics & Gynecology
Jia-Pei Wu, Liao Peng, Xiao Zeng, Hao Li, Hong Shen, De-Yi Luo
Summary: Imidafenacin showed similar efficacy to other anticholinergic drugs in treating overactive bladder syndrome, but performed better in reducing nocturia episodes, and had lower rates of dry mouth and constipation, as well as higher adherence and persistence among patients.
INTERNATIONAL UROGYNECOLOGY JOURNAL
(2021)
Review
Urology & Nephrology
Blayne Welk, Kathryn Richardson, Jalesh N. Panicker
Summary: Overactive bladder (OAB) is commonly treated with anticholinergic medications, which may affect cognitive function in the short term and potentially increase the risk of dementia in the long term. Careful consideration of cognitive impairment risk factors and related factors is important when selecting anticholinergic agents for OAB treatment.
NATURE REVIEWS UROLOGY
(2021)
Article
Urology & Nephrology
Malgorzata Baka-Ostrowska, David T. Bolong, Cristian Persu, Camilla Tondel, Achim Steup, Christopher Lademacher, Nancy Martin
Summary: The study aimed to evaluate the efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity. The results showed that mirabegron was effective and well-tolerated in the treatment of pediatric patients with NDO.
NEUROUROLOGY AND URODYNAMICS
(2021)
Article
Pharmacology & Pharmacy
Yining Qiang, Lu Bai, Shuran Tian, Yi Ma, Pingxiang Xu, Mingchang Cheng, Yi Wu, Xiaorong Li, Ming Xue, Xuelin Zhou
Summary: This study found that daidzein in Puerariae Lobatae Radix extract can treat OAB by inhibiting the M3 receptor, while the other compounds in the extract do not have this activity. Daidzein can bind to the M3 receptor via hydrogen bonding and increase its melting temperature.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Liping Xia, Huilei Yan, Yalei Sun, Yan Zhu, Yudong Wu, Zhipeng Chen, Shunye Su
Summary: Tibial nerve stimulation (TNS) is as effective as antimuscarinic agents in treating overactive bladder (OAB) syndrome, with a significantly lower discontinuation rate and adverse events in the TNS group.
Article
Urology & Nephrology
Geoffroy de Sallmard, Marie-Aimee Perrouin-Verbe, Benoit Peyronnet, Xavier Biardeau, Delphine Maucort-Boulch, Emmanuel Chartier-Kastler, Veronique Phe, Alexia Even, Charles Joussain, Ines Dominique, Gerard Amarenco, Xavier Game, Christian Saussine, Alain Ruffion
Summary: The study found that IBTI has good efficacy and safety for treating idiopathic overactive bladder in patients with an artificial urinary sphincter.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Scott Macdiarmid, David B. Glazier, Rebecca J. Mccrery, Michael J. Kennelly, Mariana Nelson, Kimberly Becker Ifantides, Kurt A. Mccammon
Summary: This study evaluated the efficacy and safety of an unapproved alternative injection paradigm targeting the lower bladder for the treatment of overactive bladder. The results showed that onabotulinumtoxinA had superior efficacy compared to placebo in reducing urinary incontinence, voiding frequency and urgency, as well as improving quality of life.
NEUROUROLOGY AND URODYNAMICS
(2023)
Review
Urology & Nephrology
Kazuna Tsubouchi, Hisatomi Arima, Makiko Abe, Hiroshi Matsuzaki, Kosuke Tominaga, Aiko Fujikawa, Naotaka Gunge, Takeshi Miyazaki, Yu Okabe, Nobuyuki Nakamura, Hirofumi Matsuoka, Shota Okutsu, Kazuhiro Tada, Nobuhiro Haga
Summary: This meta-analysis investigated the effect of pharmacotherapy for overactive bladder on urinary tract infection. The results showed that antimuscarinic agents significantly increased the incidence of urinary tract infection and lower urinary tract symptoms and dysfunction, while beta 3-adrenoceptor agonists did not.
JOURNAL OF UROLOGY
(2023)